Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges
Alimentary Pharmacology & Therapeutics · 2023-09 · 58 (5) · 492-502
DOI: 10.1111/apt.17622 ↗At a glance
Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, published online on 2023-06-29. Written by Axel Dignass and 3 co-authors. Institution: Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany. Major MEDLINE topics: Inflammatory Bowel Diseases, Colitis, Ulcerative. Cited 43 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AbbVie.
Abstract (original language)
Background
With the introduction of novel therapies for inflammatory bowel diseases (IBD), ‘treat‐to‐target’ strategies are increasingly discussed to improve short‐ and long‐term outcomes in patients with IBD.
Aim
To discuss opportunities and challenges of a treat‐to‐target approach in light of the current ‘Selecting Therapeutic Targets in Inflammatory Bowel Disease’ (STRIDE‐II) consensus Methods The 2021 update of STRIDE‐II encompasses 13 evidence‐ and consensus‐based recommendations for treat‐to‐target strategies in adults and children with IBD. We highlight the potential implications and limitations of these recommendations for clinical practice.
Results
STRIDE‐II provides valuable guidance for personalised IBD management. It reflects scientific progress as well as increased evidence of improved outcomes when more ambitious treatment goals such as mucosal healing are achieved.
Conclusions
Prospective studies, objective criteria for risk stratification, and better predictors of therapeutic response are needed to potentially render ‘treating to target’ more effective in the future.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany.
- Department of Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
- Department of Internal Medicine IV, University Hospital Jena, Jena, Germany.
ORCID profiles: Axel Dignass, Stefan Rath, Andreas Stallmach
Funding
- AbbVie
Cite
APA
Dignass, A., Rath, S., Kleindienst, T., & Stallmach, A. (2023). Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges. Alimentary Pharmacology & Therapeutics, 58(5), 492-502. https://doi.org/10.1111/apt.17622
Vancouver
Dignass A, Rath S, Kleindienst T, Stallmach A. Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges. Alimentary Pharmacology & Therapeutics. 2023;58(5):492-502. doi:10.1111/apt.17622
BibTeX
@article{Dignass2023,
author = {Dignass, Axel and Rath, Stefan and Kleindienst, Thomas and Stallmach, Andreas},
title = {Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {58},
number = {5},
pages = {492--502},
doi = {10.1111/apt.17622}
}
EUVIMED